- Home
- ALXO vs SKYE Comparison
ALXO vs SKYE Comparison
Compare ALXO & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- SKYE
- Stock Information
- Founded
- ALXO 2015
- SKYE 2012
- Country
- ALXO United States
- SKYE United States
- Employees
- ALXO N/A
- SKYE N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- SKYE Health Care
- Exchange
- ALXO Nasdaq
- SKYE Nasdaq
- Market Cap
- ALXO 76.5M
- SKYE 80.7M
- IPO Year
- ALXO 2020
- SKYE N/A
- Fundamental
- Price
- ALXO $1.12
- SKYE $2.98
- Analyst Decision
- ALXO Buy
- SKYE Buy
- Analyst Count
- ALXO 6
- SKYE 6
- Target Price
- ALXO $6.64
- SKYE $18.67
- AVG Volume (30 Days)
- ALXO 769.2K
- SKYE 223.9K
- Earning Date
- ALXO 03-06-2025
- SKYE 02-25-2025
- Dividend Yield
- ALXO N/A
- SKYE N/A
- EPS Growth
- ALXO N/A
- SKYE N/A
- EPS
- ALXO N/A
- SKYE N/A
- Revenue
- ALXO N/A
- SKYE N/A
- Revenue This Year
- ALXO N/A
- SKYE N/A
- Revenue Next Year
- ALXO N/A
- SKYE N/A
- P/E Ratio
- ALXO N/A
- SKYE N/A
- Revenue Growth
- ALXO N/A
- SKYE N/A
- 52 Week Low
- ALXO $0.96
- SKYE $2.31
- 52 Week High
- ALXO $17.83
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- ALXO 38.53
- SKYE 48.34
- Support Level
- ALXO $1.00
- SKYE $2.97
- Resistance Level
- ALXO $1.22
- SKYE $3.31
- Average True Range (ATR)
- ALXO 0.09
- SKYE 0.37
- MACD
- ALXO 0.00
- SKYE 0.01
- Stochastic Oscillator
- ALXO 35.12
- SKYE 40.00
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.